The Nasdaq is turning lower this morning as Apple (NASDAQ:AAPL) weighs it down. AAPL is down about 10% from its over $700 highs in September. Apple isn’t the only Nasdaq stock heading lower today, let’s take a look at six more that are struggling.
Delcath Systems, Inc. (NASDAQ:DCTH) is down 18.18% today at $1.71. DCTH has traded 3.2 million shares so far today, well above its daily average of 1.05 million shares. Delcath said today the FDA has accepted its cancer treatment system for a standard review. Delcath said that the review should be completed within 10 months of submission. The company submitted the application on Aug. 15. The company has a market cap of 111.80 million.
Amedisys Inc. (NASDAQ:AMED) is down 9.98% today at $12.00. AMED has traded 289 thousand shares so far today, above its average of 274 thousand shares. AMED shares are down today after cutting its revenue outlook due to a new contract with Humana. The company has a market cap of 366.11 million.
ChipMOS Technologies LTD. (NASDAQ:IMOS) is down 8.57% today at $12.81. IMOS has traded 280 thousand shares so far today, well above its daily average of 167 thousand shares. The company has a market cap of 352.29 million.
American Capital Agency Corp. (NASDAQ:AGNC) is down 5.28% today at $30.87. AGNC has traded 21.8 million shares so far today, 3 times its daily average. AGNC shares have dropped more than 10% over the past five days and nearly 18% over the past month. American Capital Agency has a market cap of 10.21 billion.
American Capital Mortgage Investment (NASDAQ:MTGE) is down 6.17% this morning at $22.95. MTGE has traded 1.8 million shares so far today, more than double its daily average. MTGE shares have fallen more than 10% over the past week. The company has a market cap of 818.43 million.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is down 2.13% in early trading at $26.47. SRPT has traded 2.9 million shares so far today, 500 thousand shares more than its daily average. SRPT shares have been pulling back recently after the stock shot up from $15 to $45 earlier this month. Sarepta did receive positive comments from Wedbush and Piper Jaffray today on its Duchenne Muscular Dystrophy treatment. The company has a market cap of 594.98 million.
About Kyle Pinder
